Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial.
Saved in:
| Title: | Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial. |
|---|---|
| Authors: | Lim, Endry H. T.1,2,3,4,5 (AUTHOR) e.lim@amsterdamumc.nl, Vlaar, Alexander P. J.1,2 (AUTHOR), Bos, Lieuwe D. J.1,2 (AUTHOR), van Vught, Lonneke A.1,6 (AUTHOR), Boer, Anita M. Tuip-de1,2 (AUTHOR), Dujardin, Romein W. G.1,2 (AUTHOR), Habel, Maria7 (AUTHOR), Xu, Zhongli7 (AUTHOR), Brouwer, Matthijs C.3,4 (AUTHOR), van de Beek, Diederik3,4 (AUTHOR), de Bruin, Sanne1,2 (AUTHOR), the Amsterdam UMC COVID-19 Biobank Investigators (AUTHOR), van Agtmael, Michiel (AUTHOR), Algera, Anne Geke (AUTHOR), Appelman, Brent (AUTHOR), van Baarle, Floor (AUTHOR), Beudel, Martijn (AUTHOR), Bogaard, Harm Jan (AUTHOR), Bomers, Marije (AUTHOR), Bonta, Peter (AUTHOR) |
| Source: | Respiratory Research. 12/24/2022, Vol. 23 Issue 1, p1-6. 6p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 14659921 |
|---|---|
| DOI: | 10.1186/s12931-022-02278-1 |
